TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9230725
Drug: Regular anthelminthic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular anthelminthic treatment with albendazole for 1 year
Study: 9230725
Drug: Regular anthelminthic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular anthelminthic treatment with albendazole
Study: 3629189
Drug: Graded fundic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded fundic distension with a balloon to 150 ml
Study: 3629189
Drug: Graded fundic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded fundic distension with a balloon to 300 ml
Study: 3629189
Drug: Graded fundic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded fundic distension with a balloon to 600 ml
Study: 3629189
Drug: Continuous fundic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous fundic distension with a volume of 300 ml for 2 1/2 h
Study: 3629189
Drug: Anticholinergic drug
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic drug benzilonium bromide during 30 min of fundic distension to 150 ml
Study: 29351007
Drug: Early renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early renal replacement therapy (RRT) initiation strategy
Study: 29351007
Drug: Delayed renal
Normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Delayed renal replacement therapy (RRT) initiation strategy
Study: 28103388
Drug: Low-dose retinol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose retinol (0.02%) + Climbazole (0.5%)
Study: 21570513
Drug: Abciximab (abx)
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab (abx) combination therapy
Study: 18285668
Drug: Oseltamivir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir treatment for influenza A
Study: 18285668
Drug: Oseltamivir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir treatment for influenza B
Study: 12967058
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 10 mg/day
Study: 11034112
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin (1 mg)
Study: 31970414
Drug: HDAC8 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HDAC8 inhibitor
Study: 21211891
Drug: Open treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open treatment (Class 2b)
Study: 21211891
Drug: Closed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed treatment (Class 2a)
Study: 19370950
Drug: Doxofylline (400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxofylline (400mg twice daily)
Study: 12360456
Drug: Alosetron (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron (1-4 mg twice daily)
Study: 10486645
Drug: Caucasian women
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caucasian women (CC)
Study: 8735683
Drug: Medroxyprogesterone 10
Normalized name: medroxyprogesterone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxyprogesterone 10 mg
Study: 1748539
Drug: labetalol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol (400 mg to 600 mg per day)
Study: 26798966
Drug: LY900009 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY900009 at 30 mg
Study: 26798966
Drug: LY900009 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY900009 at 15 mg
Study: 24687576
Drug: Pre-warmed intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-warmed intravenous fluids (approximately 41 °C)
Study: 24687576
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature intravenous fluids
Study: 19320679
Drug: Immediate postal
Normalized name: APPLE 500 mg in 50 mL TOPICAL SOLUTION [Mostal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate postal treatment for 3 months
Study: 19320679
Drug: Delayed postal
Normalized name: APPLE 500 mg in 50 mL TOPICAL SOLUTION [Mostal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed postal treatment (months 3-6)
Study: 11150109
Drug: Fludrocortisone acetate,
Normalized name: Fludrocortisone Acetate, 0.1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone acetate, titrated to 0.1 mg/d (n = 50)
Study: 12045581
Drug: Ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (4 mg intravenously)
Study: 7946179
Drug: Isradipine at
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine at 2.5 mg/day
Study: 7946179
Drug: Nitrendipine at
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine at 10 mg/day
Study: 7946179
Drug: Nitrendipine at
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine at 10 mg/day + Aspirin at 100 mg/day
Study: 7946179
Drug: Isradipine at
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine at 2.5 mg/day + Aspirin at 100 mg/day
Study: 3182156
Drug: Moderate-protein (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-protein (0.8 g.kg‐1.d‐1), high-carbohydrate hypoenergy diet (MP/HC)
Study: 3182156
Drug: High-protein (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein (1.6 g.kg‐1.d‐1), moderate-carbohydrate hypoenergy diet (HP/MC)
Study: 31311598
Drug: PCV7 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV7 (3 doses)
Study: 24013347
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with accelerated rehabilitation protocol
Study: 19061152
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg t.i.d for 20 weeks
Study: 12866134
Drug: Beta-blockers (control)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (control)
Study: 10370677
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus high-dose, intermittent IL-2 (2.1 x 10(6) U twice weekly)
Study: 10370677
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus low-dose, continuous IL-2 (7 x 10(5) U daily)
Study: 8912507
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Fluoxetine and Amitriptyline
Study: 1676832
Drug: Idazoxan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (40 mg tid)
Study: 6859669
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume (V(T)) of 14 ml/kg
Study: 6859669
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume (V(T)) of 11 ml/kg
Study: 6859669
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume (V(T)) of 7 ml/kg
Study: 6859669
Drug: High tidal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tidal volume (>12 ml/kg)
Study: 28264692
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) provided by a multidisciplinary team
Study: 28264692
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) provided by a multidisciplinary team and Short Message Service (SMS)
Study: 25919473
Drug: Combined intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intra-articular and rotator interval injection
Study: 25919473
Drug: Intra-articular corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular corticosteroid injection and Combined intra-articular/interval injection
Study: 21279511
Drug: Glutamine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (3 g/day)
Study: 23062837
Drug: Atomoxetine (ATX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (ATX), mean daily dosage 71.6±14.9mg, treatment duration 12 weeks
Study: 21741092
Drug: Grass AIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass AIT (Phleum pratense grass pollen allergen extract), once-daily for 8 to 10 weeks
Study: 1328364
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg) + Benazepril (10 mg)
Study: 6108817
Drug: SKF 92
Normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKF 92 657 at 1.0 mg/kg
Study: 6108817
Drug: SKF 92
Normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKF 92 657 at 2.0 mg/kg
Study: 6108817
Drug: SKF 92
Normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKF 92 657 at 4.0 mg/kg
Study: 6108817
Drug: SKF 92
Normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKF 92 657 at 8.0 mg/kg
Study: 31159849
Drug: ASICA intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASICA intervention (tablet-based digital intervention to prompt and support TSSE)
Study: 27853163
Drug: Sacubitril/valsartan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan 200 mg QD, uptitrated to 400 mg QD if BP uncontrolled after 4 weeks, followed by amlodipine 5-10 mg and hydrochlorothiazide 6.25-25 mg if needed
Study: 27853163
Drug: Sacubitril/valsartan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan 200 mg QD
Study: 25483230
Drug: Lutein and
Normalized name: ICaps Lutein and Omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein and Zeaxanthin supplements (n=54)
Study: 19845256
Drug: Topical 10%
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 10% phenylephrine cream
Study: 19845256
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (Control)
Study: 10524837
Drug: Lamotrigine 50
Normalized name: lamotrigine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 50 mg/day
Study: 6786071
Drug: Protein-calorie replacement
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-calorie replacement therapy (immediate sensitization to dinitrochlorobenzene)
Study: 6786071
Drug: Protein-calorie replacement
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-calorie replacement therapy (sensitization after 1 week)
Study: 6786071
Drug: Protein-calorie replacement
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-calorie replacement therapy (sensitization after 2 weeks)
Study: 6786071
Drug: Protein-calorie replacement
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-calorie replacement therapy (sensitization after 3 weeks)
Study: 6786071
Drug: Attempted sensitization
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attempted sensitization before refeeding in children with total serum proteins < 4.5 g/dl
Study: 28549665
Drug: High nitrate‐containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: High nitrate‐containing beetroot juice (BRJ) consumed daily (8 mmol nitrate for HTN) or three times a week (6.1 mmol nitrate for HFpEF)
Study: 25163639
Drug: Probiotic preparation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic preparation containing Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium lactis, fructooligosaccharide, galactooligosaccharide, colostrums and lactoferrin (NBL probiotic ATP®)
Study: 23474363
Drug: Capecitabine (830
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (830 mg/m² twice daily, Monday to Friday) with radiation (50.4 Gy in 28 fractions)
Study: 23474363
Drug: Gemcitabine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (300 mg/m² once per week) with radiation (50.4 Gy in 28 fractions)
Study: 21320365
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g RBO spread (RBOS)
Study: 21320365
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g phytosterol-enriched spread (PS)
Study: 21320365
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g standard spread (SS)
Study: 21320365
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g RBOS plus 30 ml RBO
Study: 21320365
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g SS plus 30 ml sunflower oil
Study: 16928840
Drug: No spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: No spray (control)
Study: 10788675
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light treatment (2-h exposure to 2500 lux between 14.00 and 16.00 h)
Study: 10788675
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise and bright light treatment
Study: 8840941
Drug: Intravenous push
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous push of iron dextran 100 mg over 2 minutes (undiluted)
Study: 8840941
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of iron dextran 100 mg over 30 minutes
Study: 8840941
Drug: Cost-minimization analysis
Normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost-minimization analysis of intravenous push administration
Study: 6401911
Drug: Cysteine‐HCl supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteine‐HCl supplemented total parenteral nutrition
Study: 30382737
Drug: iDOVE intervention
Normalized name: Dove DermaSeries
Approvals — FDA: no, EMA: no, PMDA: no
Description: iDOVE intervention (cognitive-behavioral therapy and motivational interviewing-based intervention with a brief in-ED session and 8 weeks of automated text-message daily mood queries)
Study: 30382737
Drug: Control (brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (brief in-ED presentation and twice-weekly text messages on healthy behaviors)
Study: 27022679
Drug: Oral 50,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 50,000 IU/wk Vitamin D3 (cholecalciferol) for 52 weeks
Study: 27022679
Drug: Oral 50,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 50,000 IU/wk Vitamin D3 (cholecalciferol) for 52 weeks (stratified by depression types)
Study: 20630682
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (nadroparin 180 anti-activated factor X units once daily for 10 days) plus compression therapy for three months
Study: 9203881
Drug: Neostigmine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (100 micrograms in 1 ml of saline)
Study: 9203881
Drug: Morphine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (100 micrograms in 1 ml of saline)
Study: 7970115
Drug: Individualized dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized dialysis prescription using urea kinetic modelling (UKM)
Study: 3308737
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (1 g twice daily)
Study: 3308737
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Calcium and Ascorbic acid)
Study: 25200399
Drug: AREDS formulation
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AREDS formulation (AF)
Study: 20048183
Drug: Idarubicin (IDA3;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin (IDA3; 12 mg/m(2)/d x 3 days)
Study: 20048183
Drug: Idarubicin (IDA4;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin (IDA4; 12 mg/m(2)/d x 4 days)
Study: 20048183
Drug: Daunorubicin (DNR;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin (DNR; 80 mg/m(2)/d x 3 days)
Study: 20048183
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of idarubicin (IDA3; 12 mg/m(2)/d x 3 days)
Study: 20048183
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with rIL-2
Study: 16635225
Drug: rhIL-11 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-11 (1 mg once weekly)
Study: 16635225
Drug: prednisolone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone (60 mg/day)
Study: 12792544
Drug: GoreTex (W.L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: GoreTex (W.L. Gore) repair
Study: 2024739
Drug: Secobarbital (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secobarbital (100 mg daily)
Study: 2024739
Drug: Secobarbital (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secobarbital (200 mg daily)
Study: 2024739
Drug: Ethanol (1
Normalized name: ALCOHOL 95 mL in 100 mL TOPICAL SOLUTION [95% Ethanol (190 Proof)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (1 g/kg daily)
Study: 6120716
Drug: Intravenous propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propranolol or metoprolol
Study: 6120716
Drug: Intravenous frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous frusemide
Study: 6120716
Drug: Prior oral
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior oral metoprolol or propranolol
Study: 24702815
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (0.4 U/kg therapeutic dose)
Study: 24702815
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (0.8 U/kg high dose)
Study: 18626423
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 4 mg (0.1 cc) of triamcinolone acetonide at the end of surgery
Study: 12403927
Drug: Established antihistamine
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established antihistamine treatment
Study: 9972747
Drug: Routine transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine transfusion therapy
Study: 8788983
Drug: Baclofen (GABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (GABA receptor ligand) for 3 weeks
Study: 8788983
Drug: Sybazon preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sybazon preparation
Study: 2260157
Drug: Nimodipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (2 mg/hr constant intravenous infusion for 5 days, 120 mg/day orally for another 16 days)
Study: 6355877
Drug: Extensive plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extensive plasma exchanges (PE) plus conventional corticosteroid/azathioprine treatment
Study: 6355877
Drug: Conventional corticosteroid/azathioprine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional corticosteroid/azathioprine treatment
Study: 27743448
Drug: Long-term weekly
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term weekly supragingival irrigations with aerosolized 0.5% hydrogen peroxide
Study: 25373733
Drug: Bortezomib plus
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib plus Bevacizumab (15 mg/kg Bevacizumab and 1.3 mg/m2 Bortezomib)
Study: 7484032
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 1% mepivacaine (10 mg/ml)
Study: 7484032
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of 1% mepivacaine (10 mg/ml)
Study: 7372262
Drug: Solugastril Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solugastril Gel (3 sachets daily)
Study: 7372262
Drug: Solugastril Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solugastril Gel combined with Solu-Vetan
Study: 28800989
Drug: Intraluminal placement
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraluminal placement of 9-French Arndt bronchial blocker
Study: 28800989
Drug: Extraluminal placement
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraluminal placement of 9-French Arndt bronchial blocker
Study: 26308766
Drug: Positive antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive antibody titers postinduction
Study: 26308766
Drug: Negative antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative antibody titers
Study: 26308766
Drug: Positive antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive antibody titers
Study: 16622270
Drug: Neoadjuvant (primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant (primary systemic) treatment for operable breast cancer
Study: 8256886
Drug: Thiorphan (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiorphan (2.5 mg/ml concentration, 0.5 ml nebulized dose)
Study: 29514306
Drug: Monovalent rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent rotavirus vaccine
Study: 26329347
Drug: Telmisartan/rosuvastatin fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan/rosuvastatin fixed-dose combination (80/20 mg)
Study: 26329347
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of telmisartan 80 mg and rosuvastatin 20 mg
Study: 18498589
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of dental implants